Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131220 | 0.83 | MAPT (0.55) | MAPTCA12SOS1MEN1KMT2A | |
| SCHEMBL9978289 | 0.82 | MAPT (0.69) | MAPTCA12SOS1MEN1KMT2A | |
| SCHEMBL14935499 | 0.82 | MAPT (0.69) | MAPTCA12SOS1MEN1KMT2A | |
| SCHEMBL114440 | 0.82 | MAPT (0.58) | MAPTCA12SOS1MEN1KMT2A | |
| SCHEMBL11049170 | 0.82 | MAPT (0.69) | MAPTCA12SOS1MEN1KMT2A | |
| SCHEMBL9968005 | 0.80 | ERN1 (0.71) | MAPTMEN1KMT2AALDH1A1GAA | |
| SCHEMBL11296000 | 0.80 | MAPT (0.67) | MAPTCA12SOS1MEN1KMT2A | |
| SCHEMBL11299049 | 0.80 | MAPT (0.67) | MAPTCA12SOS1MEN1KMT2A | |
| 2-Nitrobenzaldehyde SCHEMBL5654 | 0.80 | ERN1 (0.66) | MAPTCA12SOS1MEN1KMT2A | |
| 2-Nitrobenzaldehyde SCHEMBL29672618 | 0.80 | ERN1 (0.66) | MAPTCA12SOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110305039-A | A kind of application of novel fluorescence enhancement type probe in detection hydrogen sulfide | 孙治刚 | 2019-10-08 | — | — | CN | claimed |
| CN-1024192-C | Process for preparing 1,4-dihydro-pyridine derivatives | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1994-04-13 | — | — | CN | claimed |
| EP-0214708-B1 | GRISEOLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE | SANKYO COMPANY LIMITED (JP) | 1989-12-13 | — | — | EP | claimed |
| CN-1037505-A | 1, the preparation method of 4-dihydro-pyridine derivate | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1989-11-29 | — | — | CN | claimed |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| WO-2005037779-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
| CN-1024192-C | Process for preparing 1,4-dihydro-pyridine derivatives | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1994-04-13 | — | — | CN | disclosed |
| US-5216157-A | Useful for preparation of nifedipine a calcium antagonist used in treatment of hypertension | EGIS GYOGYSZERGYAR (HU) | 1993-06-01 | — | — | US | disclosed |
| US-5126457-A | Reacting nitrophenyl imines or diimines with methyl acetoacetate and amino or ammonium compounds yields high purity Nifedipine | EGIS GYOGYSZERGYAR (HU) | 1992-06-30 | — | — | US | disclosed |
| US-5126457-A | Reacting nitrophenyl imines or diimines with methyl acetoacetate and amino or ammonium compounds yields high purity Nifedipine | EGIS GYOGYSZERGYAR (HU) | 1992-06-30 | — | — | US | disclosed |
| CN-1037505-A | 1, the preparation method of 4-dihydro-pyridine derivate | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1989-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | MAPT 4772/4885CA12 1313/4885SOS1 4578/4885 |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | MAPT 2870/4885CA12 3547/4885SOS1 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.